CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$4.68 USD
-0.11 (-2.30%)
Updated Jul 25, 2024 03:51 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLGN 4.68 -0.11(-2.30%)
Will CLGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLGN
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?
Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?
CLGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
Other News for CLGN
CollPlant Innovates with 200cc Bio-Printed Breast Implants
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CollPlant bio-prints 200cc commercial-size regenerative breast implants
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Collplant Holdings (CLGN) and Zimmer Biomet Holdings (ZBH)
CollPlant Biotechnologies Ltd. (CLGN) Q1 2024 Earnings Call Transcript